血清HBV大、中、小表面蛋白检测的临床意义

庄辉

doi:10.3969/j.issn.1001-5256.2022.03.007

血清HBV大、中、小表面蛋白检测的临床意义

DOI: 10.3969/j.issn.1001-5256.2022.03.007

庄辉^,

北京大学医学部，北京 100191

利益冲突声明: 作者声明不存在利益冲突。

详细信息

通信作者:
庄辉，zhuangbmu@126.com

计量
- 文章访问数: 921
- HTML全文浏览量: 181
- PDF下载量: 145
- 被引次数: 0
出版历程
- 收稿日期: 2022-02-19
- 录用日期: 2022-02-21
- 出版日期: 2022-03-20

Clinical significance of determining the serum levels of large, middle, and small hepatitis B virus surface proteins

Hui ZHUANG^,

Peking University Health Science Center, Beijing 100191, China

More Information

Corresponding author: ZHUANG Hui, zhuangbmu@126.com

摘要

摘要: 本文综述了HBV大、中、小表面蛋白相关研究进展，包括基因结构、特点、检测方法和临床意义等方面。截至目前，关于HBV大、中、小表面蛋白的临床意义尚不明确，亟需进一步研究探讨。
- 肝炎病毒, 乙型 /
- 病毒包膜蛋白质类 /
- 诊断
Abstract: This article reviews the research advances in large, middle, and small hepatitis B virus (HBV) surface proteins, including their gene structures, characteristics, detection methods, and clinical significance. Up to now, the clinical significance of large, middle, and small HBV surface proteins remains unclear and requires further studies.
- Hepatitis B Virus /
- Viral Envelope Proteins /
- Diagnosis

HTML全文

图 1 HBV体和亚病毒颗粒(引自参考文献[3])

下载: 全尺寸图片幻灯片

图 2 LHBs、MHBs和SHBs基因结构(引自参考文献[3])

注: a，LHBs、MHBs和SHBs基因结构; b，preS1和preS2区域结构。感染性区(2~77 aa); 感染-干扰豆蔻酰化前S1肽与假设的结合位点重叠; 受体结合位点: 关键的结合位点(9~18 aa)，辅助的结合位点(28~48 aa); 豆蔻酰化信号区(2~9 aa); 形成外膜的关键区: preS1(92~108 aa) 与preS2(1~5 aa)。

下载: 全尺寸图片幻灯片

图 3 HBV A~E基因型患者LHBs、MHBs和SHBs组成比较(引自参考文献[20])

下载: 全尺寸图片幻灯片

图 4 1例无并发症急性乙型肝炎患者LHBs、MHBs和HBsAg动态变化(引自参考文献[21])

下载: 全尺寸图片幻灯片

参考文献(21)

[1]	SEITZ S, URBAN S, ANTONI C, et al. Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions[J]. EMBO J, 2007, 26(18): 4160-4167. DOI: 10.1038/sj.emboj.7601841.
[2]	DRYDEN KA, WIELAND SF, WHITTEN-BAUER C, et al. Native hepatitis B virions and capsids visualized by electron cryomicroscopy[J]. Mol Cell, 2006, 22(6): 843-850. DOI: 10.1016/j.molcel.2006.04.025.
[3]	GLEBE D, BREMER CM. The molecular virology of hepatitis B virus[J]. Semin Liver Dis, 2013, 33(2): 103-112. DOI: 10.1055/s-0033-1345717.
[4]	RANEY AK, EASTON AJ, MILICH DR, et al. Promoter-specific transactivation of hepatitis B virus transcription by a glutamine- and proline-rich domain of hepatocyte nuclear factor 1[J]. J Virol, 1991, 65(11): 5774-5781. DOI: 10.1128/JVI.65.11.5774-5781.1991.
[5]	CATTANEO R, WILL H, HERNANDEZ N, et al. Signals regulating hepatitis B surface antigen transcription[J]. Nature, 1983, 305(5932): 336-338. DOI: 10.1038/305336a0.
[6]	VYAS GN, WILLIAMS EW, KLAUS GG, et al. Hepatitis-associated Australia antigen. Protein, peptides and amine acid composition of purified antigen with its use in determining sensitivity of the hemagglutination test[J]. J Immunol, 1972, 108(4): 1114-1118.
[7]	CHAIREZ R, STEINER S, MELNICK JL, et al. Glycoproteins associated with hepatitis B antigen[J]. Intervirology, 1973, 1(3): 224-228. DOI: 10.1159/000148850.
[8]	DREESMAN GR, HOLLINGER FB, MELNICK JL. Biophysical and biochemical properties of purified preparations of hepatitis B surface antigen (HBsAg)[J]. Am J Med Sci, 1975, 270(1): 123-129. DOI: 10.1097/00000441-197507000-00018.
[9]	GERIN JL, HOLLAND PV, PURCELL RH. Australia antigen: Large-scale purification from human serum and biochemical studies of its proteins[J]. J Virol, 1971, 7(5): 569-576. DOI: 10.1128/JVI.7.5.569-576.1971.
[10]	SHIH JW, GERIN JL. Immunochemistry of hepatitis B surface antigen (HBsAg): Preparation and characterization of antibodies to the constituent polypeptides[J]. J Immunol, 1975, 115(3): 634-639.
[11]	REICH-D'ALMEIDA FB, HOCKLEY DJ. In situ reactivity of the retinal pigment epithelium. Ⅱ. Phagocytosis in the dystrophic rat[J]. Exp Eye Res, 1975, 21(4): 347-357. DOI: 10.1016/0014-4835(75)90045-7.
[12]	ROBINSON WS. The genome of hepatitis B virus[J]. Annu Rev Microbiol, 1977, 31: 357-377. DOI: 10.1146/annurev.mi.31.100177.002041.
[13]	HEERMANN KH, GOLDMANN U, SCHWARTZ W, et al. Large surface proteins of hepatitis B virus containing the pre-s sequence[J]. J Virol, 1984, 52(2): 396-402. DOI: 10.1128/JVI.52.2.396-402.1984.
[14]	HEERMANN KH, KRUSE F, SEIFER M, et al. Immunogenicity of the gene S and Pre-S domains in hepatitis B virions and HBsAg filaments[J]. Intervirology, 1987, 28(1): 14-25. DOI: 10.1159/000149993.
[15]	ZHU X, GONG Q, YU D, et al. Early serum hepatitis B virus large surface protein level: A stronger predictor of virological response to peginterferon alfa-2a than that to entecavir in HBeAg-positive patients with chronic hepatitis B[J]. J Clin Virol, 2013, 57(4): 318-322. DOI: 10.1016/j.jcv.2013.04.003.
[16]	PFEFFERKORN M, BÖHM S, SCHOTT T, et al. Quantification of large and middle proteins of hepatitis B virus surface antigen (HBsAg) as a novel tool for the identification of inactive HBV carriers[J]. Gut, 2018, 67(11): 2045-2053. DOI: 10.1136/gutjnl-2017-313811.
[17]	RINKER F, BREMER CM, SCHRÖDER K, et al. Quantitation of large, middle and small hepatitis B surface proteins in HBeAg-positive patients treated with peginterferon alfa-2a[J]. Liver Int, 2020, 40(2): 324-332. DOI: 10.1111/liv.14298.
[18]	BRANCACCIO G, SALPINI R, PIERMATTEO L, et al. An increase in the levels of middle surface antigen characterizes patients developing HBV-driven liver cancer despite prolonged virological suppression[J]. Microorganisms, 2021, 9(4): 752. DOI: 10.3390/microorganisms9040752.
[19]	PFEFFERKORN M, SCHOTT T, BÖHM S, et al. Composition of HBsAg is predictive of HBsAg loss during treatment in patients with HBeAg-positive chronic hepatitis B[J]. J Hepatol, 2021, 74(2): 283-292. DOI: 10.1016/j.jhep.2020.08.039.
[20]	PEIFFER KH, KUHNHENN L, JIANG B, et al. Divergent preS sequences in virion-associated hepatitis B virus genomes and subviral HBV surface antigen particles from HBV e antigen-negative patients[J]. J Infect Dis, 2018, 218(1): 114-123. DOI: 10.1093/infdis/jiy119.
[21]	GERKEN G, MANNS M, GERLICH WH, et al. Pre-S encoded surface proteins in relation to the major viral surface antigen in acute hepatitis B virus infection[J]. Gastroenterology, 1987, 92(6): 1864-1868. DOI: 10.1016/0016-5085(87)90617-2.